Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 234.13% | 16.87% | -923.59% | 200.59% | -152.34% |
| Total Depreciation and Amortization | -6.79% | 1.23% | 7.35% | 8.42% | 13.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -199.19% | -41.76% | 4,927.85% | -183.76% | 169.54% |
| Change in Net Operating Assets | 210.74% | 79.51% | -486.47% | 217.64% | -146.40% |
| Cash from Operations | -20.26% | -15.28% | -16.78% | 32.77% | -26.10% |
| Capital Expenditure | 1.58% | 29.98% | 12.79% | -6.76% | 21.14% |
| Sale of Property, Plant, and Equipment | -- | -200.00% | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.51% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,107.37% | -124.30% | -269.71% | -6.45% | 38.71% |
| Cash from Investing | -239.30% | 42.20% | -3,313.79% | -12.13% | 22.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00% | 0.00% | -- | 100.00% |
| Issuance of Common Stock | 5.88% | 0.00% | -20.93% | 0.00% | -33.33% |
| Repurchase of Common Stock | 90.88% | 77.48% | 53.09% | -300.00% | 44.65% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 96.95% | 79.75% | 54.96% | 112.60% | 45.31% |
| Foreign Exchange rate Adjustments | -154.55% | 133.33% | 427.78% | -100.00% | 114.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -295.09% | 106.47% | -169.67% | 72.68% | 488.89% |